MK3475-641
09 Dec 2020
Trial Summary
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate.
Acronym:
KEYNOTE 641
ACTRN/NCT /ethics:
NCT03834493
Scientific title:
Phase III, randomised, double-blind trial of pembrolizumab (MK-3475) plus enzalutamde vs placebo plus enzalutamide in participants with mCRPC
Sponsor / Cooperative group:
Merck Sharp & Dohme Corp.
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | Prostate |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2019-07-28 |
| Anticipated End Date | 2024-04-30 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Hsiang Tan |
| Recruitment Status | Recruiting |